Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP823726.RA_tgMV5XFKfwF2mROZY7ShLGy0u7Ivqq2jJH_s-8XTrE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP823726.RA_tgMV5XFKfwF2mROZY7ShLGy0u7Ivqq2jJH_s-8XTrE130_assertion type Assertion NP823726.RA_tgMV5XFKfwF2mROZY7ShLGy0u7Ivqq2jJH_s-8XTrE130_head.
- NP823726.RA_tgMV5XFKfwF2mROZY7ShLGy0u7Ivqq2jJH_s-8XTrE130_assertion description "[They are attractive candidates for liver cancer therapy given that GPC3 and mesothelin show high expression in HCC and CCA, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP823726.RA_tgMV5XFKfwF2mROZY7ShLGy0u7Ivqq2jJH_s-8XTrE130_provenance.
- NP823726.RA_tgMV5XFKfwF2mROZY7ShLGy0u7Ivqq2jJH_s-8XTrE130_assertion evidence source_evidence_literature NP823726.RA_tgMV5XFKfwF2mROZY7ShLGy0u7Ivqq2jJH_s-8XTrE130_provenance.
- NP823726.RA_tgMV5XFKfwF2mROZY7ShLGy0u7Ivqq2jJH_s-8XTrE130_assertion SIO_000772 21942912 NP823726.RA_tgMV5XFKfwF2mROZY7ShLGy0u7Ivqq2jJH_s-8XTrE130_provenance.
- NP823726.RA_tgMV5XFKfwF2mROZY7ShLGy0u7Ivqq2jJH_s-8XTrE130_assertion wasDerivedFrom befree-20140225 NP823726.RA_tgMV5XFKfwF2mROZY7ShLGy0u7Ivqq2jJH_s-8XTrE130_provenance.
- NP823726.RA_tgMV5XFKfwF2mROZY7ShLGy0u7Ivqq2jJH_s-8XTrE130_assertion wasGeneratedBy ECO_0000203 NP823726.RA_tgMV5XFKfwF2mROZY7ShLGy0u7Ivqq2jJH_s-8XTrE130_provenance.